CA2378473A1 - Modulation de l'activation plaquettaire - Google Patents

Modulation de l'activation plaquettaire Download PDF

Info

Publication number
CA2378473A1
CA2378473A1 CA002378473A CA2378473A CA2378473A1 CA 2378473 A1 CA2378473 A1 CA 2378473A1 CA 002378473 A CA002378473 A CA 002378473A CA 2378473 A CA2378473 A CA 2378473A CA 2378473 A1 CA2378473 A1 CA 2378473A1
Authority
CA
Canada
Prior art keywords
par4
par1
activity
compound
thrombin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002378473A
Other languages
English (en)
Inventor
Shaun R. Coughlin
Mark Kahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2378473A1 publication Critical patent/CA2378473A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des méthodes de modulation de l'activation plaquettaire induite par la thrombine par inhibition ou stimulation de l'activité des récepteurs PAR4 et PAR1 activés par des protéases. Cette méthode permet de bloquer sensiblement toute l'activation plaquettaire induite par la thrombine grâce à (1) l'inhibition de la signalisation par PAR1 et (2) l'inhibition de la signalisation par PAR4. La signalisation par chaque récepteur PAR peut être inhibée à différents niveaux moléculaires, tels que le niveau de liaison des ligands (par exemple lors de l'administration d'un antagoniste), le niveau d'activité d'un récepteur (par exemple lors du blocage de l'expression de ce récepteur dans les cellules appropriées) et/ou le niveau intracellulaire (par exemple lors du blocage de l'expression ou de l'activité d'une molécule nécessaire à l'activité dudit récepteur). Dans un autre mode de réalisation, cette méthode permet de stimuler l'activation plaquettaire induite par la thrombine par activation spécifique de PAR1 et PAR4. Ces méthodes peuvent s'appliquer in vivo, par administration des composés appropriés, ou in vitro, par exemple lors du traitement ex vivo d'un échantillon.
CA002378473A 1999-07-23 1999-08-24 Modulation de l'activation plaquettaire Abandoned CA2378473A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36048299A 1999-07-23 1999-07-23
US09/360,482 1999-07-23
PCT/US1999/019158 WO2001007072A1 (fr) 1999-07-23 1999-08-24 Modulation de l'activation plaquettaire

Publications (1)

Publication Number Publication Date
CA2378473A1 true CA2378473A1 (fr) 2001-02-01

Family

ID=23418153

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002378473A Abandoned CA2378473A1 (fr) 1999-07-23 1999-08-24 Modulation de l'activation plaquettaire

Country Status (3)

Country Link
JP (1) JP2003526625A (fr)
CA (1) CA2378473A1 (fr)
WO (1) WO2001007072A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001238366A1 (en) * 2000-02-17 2001-08-27 The Regents Of The University Of California Methods of modulating protease-activated receptor-4 (par4) activation via cathepsin
US7892565B2 (en) 2004-09-01 2011-02-22 Allergan, Inc. Degradable clostridial toxins
GB2424833B (en) * 2005-04-08 2008-12-10 Nicholas John Larkins Anti-inflammatory formulation comprising apocyanin and paeonol
US7888483B2 (en) * 2006-07-18 2011-02-15 Irm Llc Antagonists of protease activated receptor-1 (PAR1)
AU2008275992A1 (en) * 2007-07-17 2009-01-22 Irm Llc Antagonist antibodies of protease activated receptor-1 (PAR1)
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
IL297611A (en) * 2013-06-28 2022-12-01 Bioverativ Therapeutics Inc Binding of thrombin that degrades with castane and uses thereof
US20160274108A1 (en) * 2013-10-25 2016-09-22 Bristol-Myers Squibb Company Diagnostic methods for par4 antagonist therapy
MY192481A (en) 2014-01-10 2022-08-23 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
WO2019030706A1 (fr) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv Molécules d'anticorps anti-thrombine et méthodes d'utilisation en chirurgie orthopédique
WO2019035055A1 (fr) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv Molécules d'anticorps anti-thrombine et procédés d'utilisation avec des agents antiagrégants plaquettaires
IL273202B1 (en) * 2017-09-11 2024-04-01 Univ Monash Human thrombin receptor binding proteins, PAR4

Also Published As

Publication number Publication date
JP2003526625A (ja) 2003-09-09
WO2001007072A1 (fr) 2001-02-01

Similar Documents

Publication Publication Date Title
US6037324A (en) Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US8354378B2 (en) G protein coupled receptor antagonists and methods of activating and inhibiting G protein coupled receptors using the same
US5837809A (en) Mammalian opioid receptor ligand and uses
JP5554696B2 (ja) 組換え血小板コラーゲン受容体糖タンパク質ｖｉおよびその薬学的使用
Schraw et al. A role for Sec1/Munc18 proteins in platelet exocytosis
JP2003159088A (ja) 組換えトロンビンレセプターおよびそれに関連した薬剤
Palm et al. Identification of a Gs‐protein coupling domain to the β‐aderenoceptor using site‐specific synthetic peptides: Carboxyl terminus of Gsα is involved in coupling to β‐adrenoceptors
CA2378473A1 (fr) Modulation de l'activation plaquettaire
US5614370A (en) Assay to identify human C5a antagonists and agonists
US5892014A (en) DNA encoding a protease-activated receptor 3
JP2002504369A (ja) プロテアーゼ活性化レセプター４およびその使用。
EP0920630B1 (fr) Proteines de liaison au prion et leur utilisation
WO1989004834A1 (fr) Agent concurrent de l'immunoglobuline e
FI112801B (fi) Menetelmä ja välineitä kollageenin indusoiman verihiutaleaggregaation inhibiittorin tuottamiseksi
US5693758A (en) Immunoglobulin E competitor
WO2001000235A1 (fr) Proteines de liaison a la proteine prion, et leurs utilisations
Cheng et al. An inhibitor selective for collagen-stimulated platelet aggregation from the salivary glands of hard tick Haemaphysalis longicornis and its mechanism of action
WO2002057313A2 (fr) Composes de liaison et procedes d'identification de ces derniers
US20030167129A1 (en) Binding compounds and methods for identifying binding compounds
Maurice et al. Antithrombotic effect of the type III collagen-related octapeptide (KOGEOGPK) in the mouse
CA2067766A1 (fr) Recepteur peptidique liberant de la gastrine
CA2404139A1 (fr) Composes de fixation et procede d'identification de composes de fixation
CA2637006A1 (fr) Inhibiteurs specifiques des trpm2
Barnard et al. Opioid receptors
Monboisse et al. The Interaction of Human Neutrophils with Type IV Collagen Involves an Inhibitory Signal Transduction Pathway

Legal Events

Date Code Title Description
FZDE Discontinued